Leukemia Program

One of the largest and most comprehensive pediatric leukemia treatment clinics in the country

As one of the largest and most comprehensive pediatric leukemia treatment clinics in the country, we provide diagnosis, evaluation and ongoing management to over 500 pediatric patients with suspected or diagnosed acute lymphoblastic leukemia, acute myeloid leukemia and chronic leukemias each year. The Leukemia Program offers individualized therapies for every type and phase of leukemia seen in infants, children, adolescents and young adults. Leukemia treatment is delivered by a highly competent, experienced and diverse staff of doctors and cancer researchers.

Treatment and Evaluation

Treatment options include chemotherapy, Phase 1 investigational therapies, radiation therapy (both conventional and proton), bone marrow transplantation and immunotherapy. Each patient receives individualized treatment according to his or her diagnosis. In addition, we have dedicated and state-of-the-art hematology, cytogenetics, flow cytometry and molecular pathology laboratories which conduct comprehensive testing and provide timely and accurate patient results.

Clinical Trials and Novel Therapies

The Leukemia Program offers a broad portfolio of clinical trials for children with newly diagnosed leukemias, as well as those with recurrent or treatment‑resistant disease. Participation in clinical trials is considered a standard part of care, and all patients are evaluated for eligibility.

The program is nationally and internationally recognized for leadership in new drug development, cell and gene therapy, and the design and conduct of innovative clinical trials. Through its participation in the Children’s Oncology Group Pediatric Early Phase–Clinical Trial Network (COG PEP‑CTN) and the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium, Texas Children’s Cancer Center helps bring the most promising therapies to children sooner. This includes access to early‑phase clinical trials, shared expertise across leading institutions, and a collaborative approach focused on improving cure rates and quality of life.

Learn more about our clinical trials and novel therapies

Learn more about our Immunotherapy Program